董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hong Fang Song | 女 | Independent Director | 61 | 未披露 | 未持股 | 2025-11-30 |
| Leonard Post | 男 | Lead Independent Director | 74 | 50.01万美元 | 15.05 | 2025-11-30 |
| Susan Graf | 女 | Independent Director | 54 | 48.26万美元 | 6.28 | 2025-11-30 |
| Brian Liu | 男 | Independent Director | 38 | 47.51万美元 | 1.04 | 2025-11-30 |
| James J. Mulé | 男 | Independent Director | 74 | 45.76万美元 | 8.53 | 2025-11-30 |
| Victor Tong | 男 | Independent Director | 43 | 46.76万美元 | 1.04 | 2025-11-30 |
| Arthur Kuan | 男 | Chairman of the Board and Chief Executive Officer | 36 | 1192.84万美元 | 67.16 | 2025-11-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Arthur Kuan | 男 | Chairman of the Board and Chief Executive Officer | 36 | 1192.84万美元 | 67.16 | 2025-11-30 |
| Ambaw Bellete | 男 | President and Chief Operating Officer | 56 | 481.54万美元 | 40.72 | 2025-11-30 |
| Vijay Kasturi | 男 | Chief Medical Officer | 59 | 359.99万美元 | 未持股 | 2025-11-30 |
| Joshua F. Patterson | -- | General Counsel and Chief Compliance Officer | -- | 236.44万美元 | 未持股 | 2025-11-30 |
| Jim DeTore | 男 | Principal Financial and Accounting Officer | 61 | 9.60万美元 | 未持股 | 2025-11-30 |
董事简历
中英对照 | 中文 | 英文- Hong Fang Song
-
Hong Fang Song自2017年9月以来一直担任我们的董事会成员。宋女士是ORI Capital的创始人，自2015年7月起担任ORI Capital的高级合伙人。此前，宋女士于2010年1月至2015年6月担任跨国投资银行和金融服务公司高盛（Goldman Sachs）中国梦百合业务部董事总经理。宋女士拥有中国复旦大学经济学学士学位和美国克莱蒙特研究生院经济学硕士学位。
Hong Fang Song,has served as a member of Cg Oncology, Inc. board of directors since November 2015. Ms. Song is the Founder and has been a Senior Partner of ORI Capital Limited, a venture capital firm, since July 2015. Prior to ORI Capital, Ms. Song served as the Head of Healthcare Investment Banking for Greater China for Goldman Sachs. Prior to Goldman Sachs, Ms. Song was a Managing Director of Cowen, a member of the advisory board of AXA Investment Managers, a global investment management firm, and an executive board advisor to AXA Asia Pacific Holdings Limited. Ms. Hong holds a B.A. in Economics from Fudan University and an M.A. in Economics from Claremont Graduate School. - Hong Fang Song自2017年9月以来一直担任我们的董事会成员。宋女士是ORI Capital的创始人，自2015年7月起担任ORI Capital的高级合伙人。此前，宋女士于2010年1月至2015年6月担任跨国投资银行和金融服务公司高盛（Goldman Sachs）中国梦百合业务部董事总经理。宋女士拥有中国复旦大学经济学学士学位和美国克莱蒙特研究生院经济学硕士学位。
- Hong Fang Song,has served as a member of Cg Oncology, Inc. board of directors since November 2015. Ms. Song is the Founder and has been a Senior Partner of ORI Capital Limited, a venture capital firm, since July 2015. Prior to ORI Capital, Ms. Song served as the Head of Healthcare Investment Banking for Greater China for Goldman Sachs. Prior to Goldman Sachs, Ms. Song was a Managing Director of Cowen, a member of the advisory board of AXA Investment Managers, a global investment management firm, and an executive board advisor to AXA Asia Pacific Holdings Limited. Ms. Hong holds a B.A. in Economics from Fudan University and an M.A. in Economics from Claremont Graduate School.
- Leonard Post
-
Leonard Post在制药行业拥有超过35年的经验，担任过多个全球执行职位，在研究与开发候选产品方面有着丰富的经验。Post博士自2016年7月起担任Vivace Therapeutics（一家肿瘤公司，致力于针对Hippo途径的小分子）的首席科学官，也是其姊妹公司Virtuoso Therapeutics（一家从事肿瘤学双特异性抗体的公司）的首席科学官。Post从2010年2月到2016年6月在BioMarin NASDAQ:BMRN任职，担任多个职位，包括首席科学官。在此之前，Post博士曾担任Lead Therapeutics的首席科学官、Onyx Pharmaceuticals的研发高级副总裁和Parke-Davis Pharmaceuticals的发现研究Vice President。他目前也是Canaan Partners公司的顾问。Post博士是一名通过培训的病毒学家，并作为博士后在单纯疱疹病毒的工程方面做了早期工作。他获有密歇根大学（University of Michigan）化学理学学士学位，以及威斯康星大学（University of Wisconsin）生物化学博士学位。
Leonard Post,has over 35 years of experience in the pharmaceutical industry, where he has held various global executive positions and has extensive experience in the research and development of product candidates. From 2016 to January 2024, Dr. Post has served as Chief Scientific Officer of Vivace Therapeutics, an oncology company working on small molecules targeting the hippo pathway and, from 2018 to January 2024, as Chief Scientific Officer of its sister company Virtuoso Therapeutics, a company working on bispecific antibodies for oncology. Since 2018, Dr. Post has served as a director on the Board of CG Oncology (Nasdaq: CGON). From February 2010 until June 2016, Dr. Post worked at BioMarin (Nasdaq: BMRN), in various positions including Chief Scientific Officer. During that time, he oversaw the initiation of BioMarin's first gene therapy project for hemophilia A. Prior to that, Dr. Post served as Chief Scientific Officer of LEAD Therapeutics, Senior Vice President of Research & Development at Onyx Pharmaceuticals, and Vice President of Discovery Research at Parke-Davis Pharmaceuticals. He is also currently an advisor to Canaan Partners. Dr. Post is a virologist by training and did early work on the engineering of the herpes simplex virus as a post-doctoral fellow. He has a Bachelor of Science degree in Chemistry from the University of Michigan, and a Doctorate degree in Biochemistry from the University of Wisconsin. - Leonard Post在制药行业拥有超过35年的经验，担任过多个全球执行职位，在研究与开发候选产品方面有着丰富的经验。Post博士自2016年7月起担任Vivace Therapeutics（一家肿瘤公司，致力于针对Hippo途径的小分子）的首席科学官，也是其姊妹公司Virtuoso Therapeutics（一家从事肿瘤学双特异性抗体的公司）的首席科学官。Post从2010年2月到2016年6月在BioMarin NASDAQ:BMRN任职，担任多个职位，包括首席科学官。在此之前，Post博士曾担任Lead Therapeutics的首席科学官、Onyx Pharmaceuticals的研发高级副总裁和Parke-Davis Pharmaceuticals的发现研究Vice President。他目前也是Canaan Partners公司的顾问。Post博士是一名通过培训的病毒学家，并作为博士后在单纯疱疹病毒的工程方面做了早期工作。他获有密歇根大学（University of Michigan）化学理学学士学位，以及威斯康星大学（University of Wisconsin）生物化学博士学位。
- Leonard Post,has over 35 years of experience in the pharmaceutical industry, where he has held various global executive positions and has extensive experience in the research and development of product candidates. From 2016 to January 2024, Dr. Post has served as Chief Scientific Officer of Vivace Therapeutics, an oncology company working on small molecules targeting the hippo pathway and, from 2018 to January 2024, as Chief Scientific Officer of its sister company Virtuoso Therapeutics, a company working on bispecific antibodies for oncology. Since 2018, Dr. Post has served as a director on the Board of CG Oncology (Nasdaq: CGON). From February 2010 until June 2016, Dr. Post worked at BioMarin (Nasdaq: BMRN), in various positions including Chief Scientific Officer. During that time, he oversaw the initiation of BioMarin's first gene therapy project for hemophilia A. Prior to that, Dr. Post served as Chief Scientific Officer of LEAD Therapeutics, Senior Vice President of Research & Development at Onyx Pharmaceuticals, and Vice President of Discovery Research at Parke-Davis Pharmaceuticals. He is also currently an advisor to Canaan Partners. Dr. Post is a virologist by training and did early work on the engineering of the herpes simplex virus as a post-doctoral fellow. He has a Bachelor of Science degree in Chemistry from the University of Michigan, and a Doctorate degree in Biochemistry from the University of Wisconsin.
- Susan Graf
-
Susan Graf，自2023年11月起担任CG Oncology，Inc.董事会成员。格拉夫女士目前是全球生命科学交易公司Locust Walk Partners，LLC的高级顾问和常驻企业家。Graf女士此前曾于2019年8月至2021年5月担任生物技术公司Akamara Therapeutics的首席执行官。在加入Akamara Therapeutics之前，Graf女士于2016年4月至2018年9月担任生物制药公司Epizyme的首席商务官和首席财务官。在加入Epizyme之前，Graf女士在2015年被Shire收购之前曾担任NPS制药公司企业发展和战略副总裁一职。在她职业生涯的早期，格拉夫曾在罗氏公司担任过近18年的领导和行政职务。Graf女士目前担任上市微生物组疗法公司Finch Therapeutics的董事会和审计委员会主席，并担任私营制药公司Kal é o的董事会成员。格拉夫女士拥有纽约大学斯特恩商学院的工商管理硕士学位和普渡大学的药理学学士学位。
Susan Graf,has served as a member of Cg Oncology, Inc. board of directors since November 2023. Ms. Graf is currently a Senior Advisor and Entrepreneur in Residence at Locust Walk Partners, LLC, a global life science transaction firm. Ms. Graf previously served as Chief Executive Officer of biotechnology company Akamara Therapeutics from August 2019 to May 2021. Prior to Akamara Therapeutics, Ms. Graf was Chief Business Officer and Principal Financial Officer at Epizyme, a biopharmaceutical company, from April 2016 to September 2018. Prior to Epizyme, Ms. Graf held the position of Vice President, Corporate Development and Strategy for NPS Pharma before it was acquired by Shire in 2015. Earlier in her career, Ms. Graf spent nearly 18 years at Roche in a number of leadership and executive positions. Ms. Graf currently chairs the board of directors and audit committee of Finch Therapeutics, a publicly-traded microbiome therapeutics company and serves on the board of directors of Kaléo, a privately held pharmaceutical company. Ms. Graf has an M.B.A. from the Stern School of Business at New York University and a B.Pharm. from Purdue University. - Susan Graf，自2023年11月起担任CG Oncology，Inc.董事会成员。格拉夫女士目前是全球生命科学交易公司Locust Walk Partners，LLC的高级顾问和常驻企业家。Graf女士此前曾于2019年8月至2021年5月担任生物技术公司Akamara Therapeutics的首席执行官。在加入Akamara Therapeutics之前，Graf女士于2016年4月至2018年9月担任生物制药公司Epizyme的首席商务官和首席财务官。在加入Epizyme之前，Graf女士在2015年被Shire收购之前曾担任NPS制药公司企业发展和战略副总裁一职。在她职业生涯的早期，格拉夫曾在罗氏公司担任过近18年的领导和行政职务。Graf女士目前担任上市微生物组疗法公司Finch Therapeutics的董事会和审计委员会主席，并担任私营制药公司Kal é o的董事会成员。格拉夫女士拥有纽约大学斯特恩商学院的工商管理硕士学位和普渡大学的药理学学士学位。
- Susan Graf,has served as a member of Cg Oncology, Inc. board of directors since November 2023. Ms. Graf is currently a Senior Advisor and Entrepreneur in Residence at Locust Walk Partners, LLC, a global life science transaction firm. Ms. Graf previously served as Chief Executive Officer of biotechnology company Akamara Therapeutics from August 2019 to May 2021. Prior to Akamara Therapeutics, Ms. Graf was Chief Business Officer and Principal Financial Officer at Epizyme, a biopharmaceutical company, from April 2016 to September 2018. Prior to Epizyme, Ms. Graf held the position of Vice President, Corporate Development and Strategy for NPS Pharma before it was acquired by Shire in 2015. Earlier in her career, Ms. Graf spent nearly 18 years at Roche in a number of leadership and executive positions. Ms. Graf currently chairs the board of directors and audit committee of Finch Therapeutics, a publicly-traded microbiome therapeutics company and serves on the board of directors of Kaléo, a privately held pharmaceutical company. Ms. Graf has an M.B.A. from the Stern School of Business at New York University and a B.Pharm. from Purdue University.
- Brian Liu
-
Brian Liu，自2022年9月起担任CG Oncology，Inc.董事会成员。刘博士是医疗保健风险投资公司Longitude Capital的董事总经理，自2018年以来一直在该公司任职。在加入经度资本之前，刘博士于2016年1月至2018年7月担任麦肯锡公司制药业务的敬业度经理。刘博士目前担任Lassen Therapeutics的董事会成员，并担任Quanta Therapeutics.、Rivus Pharmaceuticals和Zenas BioPharma的董事会观察员。刘博士此前曾在Endeavor Biomedicines、Inflazome（已被罗氏控股收购）、Dascena Lab、Talaris Therapeutics、Vera Therapeutics担任董事会观察员。刘博士拥有斯坦福医学院的医学博士学位和约翰霍普金斯大学的生物医学工程学士学位。
Brian Liu,has served as a member of Cg Oncology, Inc. board of directors since September 2022. Dr. Liu is a Managing Director at Longitude Capital, a healthcare venture capital firm, where he has been employed since 2018. Prior to joining Longitude Capital, Dr. Liu was an Engagement Manager in the pharmaceuticals practice of McKinsey & Company from January 2016 to July 2018. Dr. Liu currently serves on the board of directors of Lassen Therapeutics and as a board observer at Quanta Therapeutics., Rivus Pharmaceuticals and Zenas BioPharma. Dr. Liu previously served as a board observer at Endeavor Biomedicines, Inflazome (acquired by Roche Holding), Dascena Lab, Talaris Therapeutics, and Vera Therapeutics. Dr. Liu holds an M.D. from Stanford School of Medicine and a B.S. in Biomedical Engineering from Johns Hopkins University. - Brian Liu，自2022年9月起担任CG Oncology，Inc.董事会成员。刘博士是医疗保健风险投资公司Longitude Capital的董事总经理，自2018年以来一直在该公司任职。在加入经度资本之前，刘博士于2016年1月至2018年7月担任麦肯锡公司制药业务的敬业度经理。刘博士目前担任Lassen Therapeutics的董事会成员，并担任Quanta Therapeutics.、Rivus Pharmaceuticals和Zenas BioPharma的董事会观察员。刘博士此前曾在Endeavor Biomedicines、Inflazome（已被罗氏控股收购）、Dascena Lab、Talaris Therapeutics、Vera Therapeutics担任董事会观察员。刘博士拥有斯坦福医学院的医学博士学位和约翰霍普金斯大学的生物医学工程学士学位。
- Brian Liu,has served as a member of Cg Oncology, Inc. board of directors since September 2022. Dr. Liu is a Managing Director at Longitude Capital, a healthcare venture capital firm, where he has been employed since 2018. Prior to joining Longitude Capital, Dr. Liu was an Engagement Manager in the pharmaceuticals practice of McKinsey & Company from January 2016 to July 2018. Dr. Liu currently serves on the board of directors of Lassen Therapeutics and as a board observer at Quanta Therapeutics., Rivus Pharmaceuticals and Zenas BioPharma. Dr. Liu previously served as a board observer at Endeavor Biomedicines, Inflazome (acquired by Roche Holding), Dascena Lab, Talaris Therapeutics, and Vera Therapeutics. Dr. Liu holds an M.D. from Stanford School of Medicine and a B.S. in Biomedical Engineering from Johns Hopkins University.
- James J. Mulé
-
James J. Mul é，自2018年起担任CG Oncology，Inc.董事会成员。Mul é博士自2003年以来一直担任转化科学副中心主任和迈克尔麦吉利库迪（美国参议员Connie Mack（退休）&家庭）授予的黑色素瘤研究和治疗主席，并且是佛罗里达州坦帕市莫菲特癌症中心的副中心主任，自2003年以来他一直担任该中心的主任。自1993年以来，Mul é博士曾多次担任FDA药物评估和研究中心、生物制品评估和研究中心以及美国国家癌症研究所（NCI）的政府特别雇员。Mul é博士还曾于2016年至2020年在上市公司Fulgent Genetics的董事会任职。Mul é博士在众多生物技术公司、制药公司、NCI指定的癌症中心和投资基金的顾问委员会任职，包括奥马哈的巴菲特癌症中心；明尼阿波利斯的共济会癌症中心；Affyimmune Therapeutics；Aleta Biotherapeutics；OncoPep；Turnstone Biologics；UBIVAC；Vault Pharma；Vycellix；和Noble Life Science Partners。Mul é博士拥有华盛顿大学和华盛顿州西雅图Fred Hutchinson癌症研究中心肿瘤免疫学、免疫细胞学和免疫病理学跨学科博士学位、华盛顿大学医学院细胞免疫学硕士学位和新泽西城市大学学士学位。Mul é博士在马里兰州贝塞斯达的美国国立卫生研究院（NIH）NCI癌症治疗部门外科分部接受了正式的研究生培训。Mul é博士曾在NCI/NIH和密歇根大学安娜堡分校担任终身高级职务。
James J. Mulé,has served as a member of Cg Oncology, Inc. board of directors since 2018. Dr. Mulé has served as Associate Center Director for Translational Science and the Michael McGillicuddy (U.S. Senator Connie Mack (ret.) & Family) Endowed Chair for Melanoma Research and Treatment since 2003 and is the Associate Center Director of the Moffitt Cancer Center, Tampa, Florida, where he has served as a Director since 2003. Since 1993,Dr. Mulé has served multiple tenures as a special government employee to the FDA at the Center for Drug Evaluation and Research and at the Center for Biologics Evaluation and Research and to the National Cancer Institute (NCI). Dr. Mulé also served on the board of directors of publicly-traded company Fulgent Genetics from 2016 to 2020. Dr. Mulé serves on the advisory boards of numerous biotechnology companies, pharmaceutical companies, NCI-designated cancer centers and investment funds, including Buffett Cancer Center, Omaha; Masonic Cancer Center, Minneapolis; Affyimmune Therapeutics; Aleta Biotherapeutics; OncoPep; Turnstone Biologics; UbiVac; Vault Pharma; Vycellix; and Noble Life Science Partners. Dr. Mulé holds an Interdisciplinary Ph.D. in Tumor Immunology, Immunocytology, and Immunopathology from the University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, Washington, a M.S. in Cellular Immunology from the University of Washington School of Medicine and a B.A. from New Jersey City University. Dr. Mulé received his formal postgraduate training at the Surgery Branch, Division of Cancer Treatment, NCI, National Institutes of Health (NIH), Bethesda, Maryland. Dr. Mulé has held tenured senior positions at the NCI/NIH and the University of Michigan, Ann Arbor. - James J. Mul é，自2018年起担任CG Oncology，Inc.董事会成员。Mul é博士自2003年以来一直担任转化科学副中心主任和迈克尔麦吉利库迪（美国参议员Connie Mack（退休）&家庭）授予的黑色素瘤研究和治疗主席，并且是佛罗里达州坦帕市莫菲特癌症中心的副中心主任，自2003年以来他一直担任该中心的主任。自1993年以来，Mul é博士曾多次担任FDA药物评估和研究中心、生物制品评估和研究中心以及美国国家癌症研究所（NCI）的政府特别雇员。Mul é博士还曾于2016年至2020年在上市公司Fulgent Genetics的董事会任职。Mul é博士在众多生物技术公司、制药公司、NCI指定的癌症中心和投资基金的顾问委员会任职，包括奥马哈的巴菲特癌症中心；明尼阿波利斯的共济会癌症中心；Affyimmune Therapeutics；Aleta Biotherapeutics；OncoPep；Turnstone Biologics；UBIVAC；Vault Pharma；Vycellix；和Noble Life Science Partners。Mul é博士拥有华盛顿大学和华盛顿州西雅图Fred Hutchinson癌症研究中心肿瘤免疫学、免疫细胞学和免疫病理学跨学科博士学位、华盛顿大学医学院细胞免疫学硕士学位和新泽西城市大学学士学位。Mul é博士在马里兰州贝塞斯达的美国国立卫生研究院（NIH）NCI癌症治疗部门外科分部接受了正式的研究生培训。Mul é博士曾在NCI/NIH和密歇根大学安娜堡分校担任终身高级职务。
- James J. Mulé,has served as a member of Cg Oncology, Inc. board of directors since 2018. Dr. Mulé has served as Associate Center Director for Translational Science and the Michael McGillicuddy (U.S. Senator Connie Mack (ret.) & Family) Endowed Chair for Melanoma Research and Treatment since 2003 and is the Associate Center Director of the Moffitt Cancer Center, Tampa, Florida, where he has served as a Director since 2003. Since 1993,Dr. Mulé has served multiple tenures as a special government employee to the FDA at the Center for Drug Evaluation and Research and at the Center for Biologics Evaluation and Research and to the National Cancer Institute (NCI). Dr. Mulé also served on the board of directors of publicly-traded company Fulgent Genetics from 2016 to 2020. Dr. Mulé serves on the advisory boards of numerous biotechnology companies, pharmaceutical companies, NCI-designated cancer centers and investment funds, including Buffett Cancer Center, Omaha; Masonic Cancer Center, Minneapolis; Affyimmune Therapeutics; Aleta Biotherapeutics; OncoPep; Turnstone Biologics; UbiVac; Vault Pharma; Vycellix; and Noble Life Science Partners. Dr. Mulé holds an Interdisciplinary Ph.D. in Tumor Immunology, Immunocytology, and Immunopathology from the University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, Washington, a M.S. in Cellular Immunology from the University of Washington School of Medicine and a B.A. from New Jersey City University. Dr. Mulé received his formal postgraduate training at the Surgery Branch, Division of Cancer Treatment, NCI, National Institutes of Health (NIH), Bethesda, Maryland. Dr. Mulé has held tenured senior positions at the NCI/NIH and the University of Michigan, Ann Arbor.
- Victor Tong
-
Victor Tong，自2023年7月起担任CG Oncology，Inc.董事会成员。Tong先生是投资公司Decheng Capital（Decheng）的董事总经理，自2012年成立以来，他一直在该公司工作，专注于对中国和美国的生物技术和医疗技术公司的投资。童先生在加入德诚集团之前，是生命科学投资公司Bay City Capital的负责人，也是摩根士丹利医疗保健投资银行部门的成员。童先生在多家私营生物技术和生物制药公司的董事会任职，包括Cellares Corp.、Epimab BioTherapeutics、Harton Therapeutics、Hummingbird Bioscience、LevitasBio、Nalu Medical、Take2和Watchmaker Genomics。Tong先生拥有加州大学伯克利分校分子和细胞生物学学士学位和工商管理学士学位。
Victor Tong,has served as a member of Cg Oncology, Inc. board of directors since July 2023. Mr. Tong is a Managing Director at Decheng Capital (Decheng), an investment firm, where he has worked since its inception in 2012 and focuses on investments in biotechnology and medical technology companies in China and the United States. Before joining Decheng, Mr. Tong was a Principal at Bay City Capital, a life sciences investment firm, and a member of the healthcare investment banking division at Morgan Stanley. Mr. Tong serves on the board of directors of multiple privately held biotechnology and biopharmaceutical companies including Cellares Corp., EpimAb Biotherapeutics, Harton Therapeutics, Hummingbird Bioscience, LevitasBio, Nalu Medical, Take2, and Watchmaker Genomics. Mr. Tong holds a B.A. in Molecular and Cell Biology and B.S. in Business Administration from the University of California, Berkeley. - Victor Tong，自2023年7月起担任CG Oncology，Inc.董事会成员。Tong先生是投资公司Decheng Capital（Decheng）的董事总经理，自2012年成立以来，他一直在该公司工作，专注于对中国和美国的生物技术和医疗技术公司的投资。童先生在加入德诚集团之前，是生命科学投资公司Bay City Capital的负责人，也是摩根士丹利医疗保健投资银行部门的成员。童先生在多家私营生物技术和生物制药公司的董事会任职，包括Cellares Corp.、Epimab BioTherapeutics、Harton Therapeutics、Hummingbird Bioscience、LevitasBio、Nalu Medical、Take2和Watchmaker Genomics。Tong先生拥有加州大学伯克利分校分子和细胞生物学学士学位和工商管理学士学位。
- Victor Tong,has served as a member of Cg Oncology, Inc. board of directors since July 2023. Mr. Tong is a Managing Director at Decheng Capital (Decheng), an investment firm, where he has worked since its inception in 2012 and focuses on investments in biotechnology and medical technology companies in China and the United States. Before joining Decheng, Mr. Tong was a Principal at Bay City Capital, a life sciences investment firm, and a member of the healthcare investment banking division at Morgan Stanley. Mr. Tong serves on the board of directors of multiple privately held biotechnology and biopharmaceutical companies including Cellares Corp., EpimAb Biotherapeutics, Harton Therapeutics, Hummingbird Bioscience, LevitasBio, Nalu Medical, Take2, and Watchmaker Genomics. Mr. Tong holds a B.A. in Molecular and Cell Biology and B.S. in Business Administration from the University of California, Berkeley.
- Arthur Kuan
-
Arthur Kuan，自CG Oncology，Inc.于2017年成立以来，一直担任CG Oncology，Inc.首席执行官和CG Oncology，Inc.董事会成员。宽先生还是全球医疗保健投资平台Ally Bridge Group的创始成员，并在Moffit癌症中心的IP商业化战略委员会任职。此前，宽先生是总部位于香港的私募股权基金Themes Investment Partners的成员，在协调投资组合公司的跨境技术转让和监管提交方面发挥了核心作用。宽先生的职业生涯始于Dinova Capital，这是一家总部位于上海的医疗技术孵化基金，负责评估医疗器械投资机会。宽先生获得了约翰霍普金斯大学的生物技术硕士学位和宾夕法尼亚大学的生物学学士学位。
Arthur Kuan,has served as Cg Oncology, Inc. Chief Executive Officer and as a member of Cg Oncology, Inc. board of directors since Cg Oncology, Inc. inception in 2017, and as Chairman since December 2023. Mr. Kuan is also a founding member of Ally Bridge Group, a global healthcare-focused investment platform, and serves on the IP Commercialization Strategy Committee at Moffit Cancer Center. Previously, Mr. Kuan was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. Mr. Kuan began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Mr. Kuan received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania. - Arthur Kuan，自CG Oncology，Inc.于2017年成立以来，一直担任CG Oncology，Inc.首席执行官和CG Oncology，Inc.董事会成员。宽先生还是全球医疗保健投资平台Ally Bridge Group的创始成员，并在Moffit癌症中心的IP商业化战略委员会任职。此前，宽先生是总部位于香港的私募股权基金Themes Investment Partners的成员，在协调投资组合公司的跨境技术转让和监管提交方面发挥了核心作用。宽先生的职业生涯始于Dinova Capital，这是一家总部位于上海的医疗技术孵化基金，负责评估医疗器械投资机会。宽先生获得了约翰霍普金斯大学的生物技术硕士学位和宾夕法尼亚大学的生物学学士学位。
- Arthur Kuan,has served as Cg Oncology, Inc. Chief Executive Officer and as a member of Cg Oncology, Inc. board of directors since Cg Oncology, Inc. inception in 2017, and as Chairman since December 2023. Mr. Kuan is also a founding member of Ally Bridge Group, a global healthcare-focused investment platform, and serves on the IP Commercialization Strategy Committee at Moffit Cancer Center. Previously, Mr. Kuan was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. Mr. Kuan began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Mr. Kuan received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.
高管简历
中英对照 | 中文 | 英文- Arthur Kuan
Arthur Kuan，自CG Oncology，Inc.于2017年成立以来，一直担任CG Oncology，Inc.首席执行官和CG Oncology，Inc.董事会成员。宽先生还是全球医疗保健投资平台Ally Bridge Group的创始成员，并在Moffit癌症中心的IP商业化战略委员会任职。此前，宽先生是总部位于香港的私募股权基金Themes Investment Partners的成员，在协调投资组合公司的跨境技术转让和监管提交方面发挥了核心作用。宽先生的职业生涯始于Dinova Capital，这是一家总部位于上海的医疗技术孵化基金，负责评估医疗器械投资机会。宽先生获得了约翰霍普金斯大学的生物技术硕士学位和宾夕法尼亚大学的生物学学士学位。
Arthur Kuan,has served as Cg Oncology, Inc. Chief Executive Officer and as a member of Cg Oncology, Inc. board of directors since Cg Oncology, Inc. inception in 2017, and as Chairman since December 2023. Mr. Kuan is also a founding member of Ally Bridge Group, a global healthcare-focused investment platform, and serves on the IP Commercialization Strategy Committee at Moffit Cancer Center. Previously, Mr. Kuan was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. Mr. Kuan began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Mr. Kuan received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.- Arthur Kuan，自CG Oncology，Inc.于2017年成立以来，一直担任CG Oncology，Inc.首席执行官和CG Oncology，Inc.董事会成员。宽先生还是全球医疗保健投资平台Ally Bridge Group的创始成员，并在Moffit癌症中心的IP商业化战略委员会任职。此前，宽先生是总部位于香港的私募股权基金Themes Investment Partners的成员，在协调投资组合公司的跨境技术转让和监管提交方面发挥了核心作用。宽先生的职业生涯始于Dinova Capital，这是一家总部位于上海的医疗技术孵化基金，负责评估医疗器械投资机会。宽先生获得了约翰霍普金斯大学的生物技术硕士学位和宾夕法尼亚大学的生物学学士学位。
- Arthur Kuan,has served as Cg Oncology, Inc. Chief Executive Officer and as a member of Cg Oncology, Inc. board of directors since Cg Oncology, Inc. inception in 2017, and as Chairman since December 2023. Mr. Kuan is also a founding member of Ally Bridge Group, a global healthcare-focused investment platform, and serves on the IP Commercialization Strategy Committee at Moffit Cancer Center. Previously, Mr. Kuan was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. Mr. Kuan began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Mr. Kuan received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.
- Ambaw Bellete
Ambaw Bellete，自2023年7月起担任CG Oncology，Inc.总裁兼首席运营官。此前，Bellete先生于2021年4月至2023年8月担任战略咨询公司Lion Healthcare Strategies的首席执行官，并于2020年3月至2021年3月担任致力于彻底改变膀胱癌治疗的基因治疗公司FerGene的首席运营官。在加入FerGene之前，Bellete先生曾担任Photocure的总裁，该公司专注于开发和商业化基于光动力技术治疗膀胱癌的医药产品，还曾在生物制药、生物技术和医疗设备公司担任多个全球领导职务，包括2012年1月至2019年7月的Medical Compression Systems总裁。Bellete先生的生物制药职业生涯始于Upjohn公司（现为辉瑞），后于赛诺菲，在专科、肿瘤科和泌尿科的业务发展、管理式护理、营销和销售职位上担任过多种领导职务。Bellete先生目前担任Axiom REACH基金会和OnCOSTING的董事会成员。Bellete先生拥有默里州立大学的生物学和化学学士学位。
Ambaw Bellete,has served as Cg Oncology, Inc. President and Chief Operating Officer since July 2023. Previously, Mr. Bellete served as Chief Executive Officer of Lion Healthcare Strategies, a strategic advisory firm, from April 2021 to August 2023, and Chief Operating Officer of FerGene, a gene therapy company dedicated to revolutionizing the treatment of bladder cancer, from March 2020 to March 2021. Prior to FerGene, Mr. Bellete served as the president of Photocure, a company focused on developing and commercializing pharmaceutical products based on photodynamic technology to treat bladder cancer, and also held several global leadership positions with biopharma, biotech and medical device companies, including President of Medical Compression Systems from January 2012 to July 2019. Mr. Bellete started his biopharma career at the Upjohn Company (now Pfizer) and then Sanofi, where he held diverse leadership roles in business development, managed care, marketing and sales positions in specialty, oncology and urology. Mr. Bellete currently serves on the board of directors The Axiom REACH Foundation and OncoSTING. Mr. Bellete holds a B.S. in Biology and Chemistry from Murray State University.- Ambaw Bellete，自2023年7月起担任CG Oncology，Inc.总裁兼首席运营官。此前，Bellete先生于2021年4月至2023年8月担任战略咨询公司Lion Healthcare Strategies的首席执行官，并于2020年3月至2021年3月担任致力于彻底改变膀胱癌治疗的基因治疗公司FerGene的首席运营官。在加入FerGene之前，Bellete先生曾担任Photocure的总裁，该公司专注于开发和商业化基于光动力技术治疗膀胱癌的医药产品，还曾在生物制药、生物技术和医疗设备公司担任多个全球领导职务，包括2012年1月至2019年7月的Medical Compression Systems总裁。Bellete先生的生物制药职业生涯始于Upjohn公司（现为辉瑞），后于赛诺菲，在专科、肿瘤科和泌尿科的业务发展、管理式护理、营销和销售职位上担任过多种领导职务。Bellete先生目前担任Axiom REACH基金会和OnCOSTING的董事会成员。Bellete先生拥有默里州立大学的生物学和化学学士学位。
- Ambaw Bellete,has served as Cg Oncology, Inc. President and Chief Operating Officer since July 2023. Previously, Mr. Bellete served as Chief Executive Officer of Lion Healthcare Strategies, a strategic advisory firm, from April 2021 to August 2023, and Chief Operating Officer of FerGene, a gene therapy company dedicated to revolutionizing the treatment of bladder cancer, from March 2020 to March 2021. Prior to FerGene, Mr. Bellete served as the president of Photocure, a company focused on developing and commercializing pharmaceutical products based on photodynamic technology to treat bladder cancer, and also held several global leadership positions with biopharma, biotech and medical device companies, including President of Medical Compression Systems from January 2012 to July 2019. Mr. Bellete started his biopharma career at the Upjohn Company (now Pfizer) and then Sanofi, where he held diverse leadership roles in business development, managed care, marketing and sales positions in specialty, oncology and urology. Mr. Bellete currently serves on the board of directors The Axiom REACH Foundation and OncoSTING. Mr. Bellete holds a B.S. in Biology and Chemistry from Murray State University.
- Vijay Kasturi
Vijay Kasturi，自2023年9月起担任CG Oncology，Inc.首席医疗官。此前，Kasturi博士于2021年4月至2023年8月担任癌症治疗公司AVEO制药的临床开发和医疗事务副总裁。在加入AVEO制药之前，Kasturi博士于2020年3月至2021年3月担任FerGene科学事务高级副总裁。在加入FerGene之前，Kasturi博士曾于2015年11月至2020年3月担任EMD Serono（一家专注于生殖健康、多发性硬化症和癌症的制药公司）的美国医疗事务、肿瘤学负责人，负责制定全球和区域战略，为免疫学、血液学和肿瘤学领域的患者带来新疗法。在他职业生涯的早期，Kasturi博士治疗癌症患者，曾担任马萨诸塞大学医学院血液肿瘤学部医学助理教授，并担任麻省大学纪念癌症中心泌尿生殖肿瘤学项目负责人。Kasturi博士在美国国家癌症研究所（NCI）接受血液肿瘤学培训，曾在NCI和达特茅斯希区柯克医学中心担任调查员和医生。Kasturi博士拥有拉什大学拉什医学院的医学博士学位和芝加哥伊利诺伊大学的生物学学士学位。
Vijay Kasturi,has served as Cg Oncology, Inc. Chief Medical Officer since September 2023. Previously, Dr. Kasturi was Vice President of Clinical Development and Medical Affairs of AVEO Pharmaceuticals, a cancer therapeutics company, from April 2021 to August 2023. Prior to AVEO Pharmaceuticals, Dr. Kasturi was Senior Vice President of Scientific Affairs at FerGene from March 2020 to March 2021. Prior to FerGene, Dr. Kasturi was head of U.S. Medical Affairs, Oncology for EMD Serono, a pharmaceutical company focused on reproductive health, multiple sclerosis and cancer, from November 2015 to March 2020, where he had responsibility for developing global and regional strategies that brought new therapies to patients in immunology, hematology and oncology. Earlier in his career, Dr. Kasturi treated patients with cancer and served as an assistant professor of medicine, Division of Hematology-Oncology at the University of Massachusetts Medical School and as the program leader for genitourinary oncology at UMass Memorial Cancer Center. Dr. Kasturi trained in Hematology-Oncology at the National Cancer Institute (NCI) and worked as an investigator and physician at the NCI and Dartmouth Hitchcock Medical Center. Dr. Kasturi holds an M.D. from Rush Medical College of Rush University and a B.S. in Biology from University of Illinois, Chicago.- Vijay Kasturi，自2023年9月起担任CG Oncology，Inc.首席医疗官。此前，Kasturi博士于2021年4月至2023年8月担任癌症治疗公司AVEO制药的临床开发和医疗事务副总裁。在加入AVEO制药之前，Kasturi博士于2020年3月至2021年3月担任FerGene科学事务高级副总裁。在加入FerGene之前，Kasturi博士曾于2015年11月至2020年3月担任EMD Serono（一家专注于生殖健康、多发性硬化症和癌症的制药公司）的美国医疗事务、肿瘤学负责人，负责制定全球和区域战略，为免疫学、血液学和肿瘤学领域的患者带来新疗法。在他职业生涯的早期，Kasturi博士治疗癌症患者，曾担任马萨诸塞大学医学院血液肿瘤学部医学助理教授，并担任麻省大学纪念癌症中心泌尿生殖肿瘤学项目负责人。Kasturi博士在美国国家癌症研究所（NCI）接受血液肿瘤学培训，曾在NCI和达特茅斯希区柯克医学中心担任调查员和医生。Kasturi博士拥有拉什大学拉什医学院的医学博士学位和芝加哥伊利诺伊大学的生物学学士学位。
- Vijay Kasturi,has served as Cg Oncology, Inc. Chief Medical Officer since September 2023. Previously, Dr. Kasturi was Vice President of Clinical Development and Medical Affairs of AVEO Pharmaceuticals, a cancer therapeutics company, from April 2021 to August 2023. Prior to AVEO Pharmaceuticals, Dr. Kasturi was Senior Vice President of Scientific Affairs at FerGene from March 2020 to March 2021. Prior to FerGene, Dr. Kasturi was head of U.S. Medical Affairs, Oncology for EMD Serono, a pharmaceutical company focused on reproductive health, multiple sclerosis and cancer, from November 2015 to March 2020, where he had responsibility for developing global and regional strategies that brought new therapies to patients in immunology, hematology and oncology. Earlier in his career, Dr. Kasturi treated patients with cancer and served as an assistant professor of medicine, Division of Hematology-Oncology at the University of Massachusetts Medical School and as the program leader for genitourinary oncology at UMass Memorial Cancer Center. Dr. Kasturi trained in Hematology-Oncology at the National Cancer Institute (NCI) and worked as an investigator and physician at the NCI and Dartmouth Hitchcock Medical Center. Dr. Kasturi holds an M.D. from Rush Medical College of Rush University and a B.S. in Biology from University of Illinois, Chicago.
- Joshua F. Patterson
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jim DeTore
Jim DeTore，将于2025年11月17日加入公司，担任临时首席财务和会计官，负责公司的财务和会计职能。在加入公司之前，2021年6月至2025年6月，Detore先生在Neurogastrx，Inc.担任首席财务官。在任职于Neurogastrx之前，2017年3月至2021年5月，Detore先生是一名独立顾问，为各种早期和中期阶段的生物技术和制药公司提供首席财务官服务。2016年8月至2017年2月，Detore先生在Proteostasis Therapeutics任职，担任首席财务官。此外，2014年11月至2016年2月，Detore先生在bluebird bio, Inc.担任首席财务官。Detore先生拥有东北大学理学学士学位和工商管理硕士学位。
Jim DeTore,will join the Company on November 17, 2025, as interim principal financial and accounting officer, responsible for the Company's financial and accounting functions. Prior to joining the Company, from June 2021 to June 2025, Mr. DeTore was Chief Financial Officer at Neurogastrx, Inc. Prior to serving at Neurogastrx, from March 2017 to May 2021, Mr. DeTore was an independent consultant providing chief financial officer services to a variety of early and mid-stage biotechnology and pharmaceutical companies, and from August 2016 to February 2017, Mr. DeTore was with Proteostasis Therapeutics, serving as Chief Financial Officer. In addition, from November 2014 to February 2016, Mr. DeTore served as Chief Financial Officer at Bluebird Bio, Inc. Mr. DeTore holds a Bachelor of Science degree and a Master of Business Administration degree from Northeastern University.- Jim DeTore，将于2025年11月17日加入公司，担任临时首席财务和会计官，负责公司的财务和会计职能。在加入公司之前，2021年6月至2025年6月，Detore先生在Neurogastrx，Inc.担任首席财务官。在任职于Neurogastrx之前，2017年3月至2021年5月，Detore先生是一名独立顾问，为各种早期和中期阶段的生物技术和制药公司提供首席财务官服务。2016年8月至2017年2月，Detore先生在Proteostasis Therapeutics任职，担任首席财务官。此外，2014年11月至2016年2月，Detore先生在bluebird bio, Inc.担任首席财务官。Detore先生拥有东北大学理学学士学位和工商管理硕士学位。
- Jim DeTore,will join the Company on November 17, 2025, as interim principal financial and accounting officer, responsible for the Company's financial and accounting functions. Prior to joining the Company, from June 2021 to June 2025, Mr. DeTore was Chief Financial Officer at Neurogastrx, Inc. Prior to serving at Neurogastrx, from March 2017 to May 2021, Mr. DeTore was an independent consultant providing chief financial officer services to a variety of early and mid-stage biotechnology and pharmaceutical companies, and from August 2016 to February 2017, Mr. DeTore was with Proteostasis Therapeutics, serving as Chief Financial Officer. In addition, from November 2014 to February 2016, Mr. DeTore served as Chief Financial Officer at Bluebird Bio, Inc. Mr. DeTore holds a Bachelor of Science degree and a Master of Business Administration degree from Northeastern University.